Clinical Trials in Philadelphia

Showing 4861-4880 of 15,860 trials

Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration

NCT06132035

This will be a randomized, comparative, parallel, clinical study to assess initial safety and tolerability of CG-P5 peptide eye drops compared to placebo in patients diagnosed with age-related wet macular degeneration

Age-related Wet Macular Degeneration

Caregen Co. Ltd.45 participantsStarted Dec 2023

Manchester, Connecticut, United States • Deerfield Beach, Florida, United States • Augusta, Georgia, United States +4 more locations

Active Not RecruitingPhase 1< 1 mile

DS-3201b in Participants With Lymphomas

NCT02732275

DS-3201b is an experimental drug that is being investigated in clinical research. Adults with non-Hodgkin lymphoma (NHL) may be able to join this study if their disease has come back after remission or is not responding to current treatment This study has three parts. The Dose Escalation part is designed is to find the safe dose of DS-3201b that adults with advanced NHL can tolerate. The Dose Expansion phase will determine how effective DS-3201b is for rare types of NH and collect additional safety data. Last, the Drug-Drug Interaction (DDI) Cohort (US Only) will evaluate the effect of DS-3201b on the pharmacokinetics (PK) of midazolam and digoxin when co-administered to patients with NHL

Lymphoma, MalignantNon-hodgkin Lymphoma

Daiichi Sankyo Co., Ltd.100 participantsStarted Mar 2016

Duarte, California, United States • New Haven, Connecticut, United States • Atlanta, Georgia, United States +17 more locations

Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration

DS-3201b in Participants With Lymphomas

Find Trials by Condition in Philadelphia

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).

Network Control TMS fMRI

Different Doses of Naronapride Vs. Placebo in Gastroparesis

myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home

A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD)

PRogrammed Versus Modified Natural Cycle After Euploid Failed Embryo Transfer

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells

Framing Eighteen Coils in Cerebral Aneurysms Trial

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD

Rituximab + Immunotherapy in Follicular Lymphoma

A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children

Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer

Comparative Effectiveness of Operative Versus Non-Operative Treatments for Rotator Cuff Tears

Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors

This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors